These AML-MSCs were derived from leukemic mice expressing MLL–AF9 oncoproteins associated with the t(9;11) (p22;q23) translocation, a model extensively used for studying AML pathogenesis [16,17,18,19]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.